×
About 8,438 results

ALLMedicine™ Mantle Cell Lymphoma Center

Research & Reviews  2,121 results

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00101101

Aug 5th, 2022 - Patients were treated with 3-6 cycles of chemotherapy +/- rituximab, with type and duration at the discretion of the individual clinician. Evaluation for response was performed 1 month after completing chemotherapy, and included computed tomograph...

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03671018

Aug 5th, 2022 - This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of intravenous mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), and in participants with follicular ...

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04930536

Aug 5th, 2022 - A prospective, multi-centre, phase IV clinical trial of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL). As per recommendation from Indian health autho...

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04939272

Aug 5th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety, tolerability, and the maximum tolerated dose (MTD) of copanlisib hydrochloride (copanlisib) and venetoclax in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). (Phase 1) II. To estimat...

A Disease Registry of Patients With Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03816683

Aug 5th, 2022 - Newer targeted therapies (monotherapy or in combination with other agents) have been recently approved in the United States for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy. The approva...

see more →

Guidelines  3 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines fo...
https://doi.org/10.1093/annonc/mdx223
Annals of Oncology : Official Journal of the European Soc... Dreyling M, Campo E et. al.

Sep 9th, 2017 - Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2017|Dreyling M,Campo E,Hermine O,Jerkeman M,Le Gouill S,|diagnosis,genetics,pathology,therapy,standards,

Non-Hodgkin's lymphomas, version 4.2014.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839265
Journal of the National Comprehensive Cancer Network : JN... Zelenetz AD, Gordon LI et. al.

Sep 6th, 2014 - Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL case...

see more →

Drugs  31 results see all →

Clinicaltrials.gov  380 results

A Disease Registry of Patients With Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03816683

Aug 5th, 2022 - Newer targeted therapies (monotherapy or in combination with other agents) have been recently approved in the United States for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least 1 prior therapy. The approva...

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04939272

Aug 5th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety, tolerability, and the maximum tolerated dose (MTD) of copanlisib hydrochloride (copanlisib) and venetoclax in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). (Phase 1) II. To estimat...

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04930536

Aug 5th, 2022 - A prospective, multi-centre, phase IV clinical trial of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL). As per recommendation from Indian health autho...

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00101101

Aug 5th, 2022 - Patients were treated with 3-6 cycles of chemotherapy +/- rituximab, with type and duration at the discretion of the individual clinician. Evaluation for response was performed 1 month after completing chemotherapy, and included computed tomograph...

A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03671018

Aug 5th, 2022 - This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of intravenous mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), and in participants with follicular ...

see more →

News  840 results

FDA Approves Tablet Formulation of Acalabrutinib (Calquence) for CLL, SLL, and MCL
https://www.medscape.com/viewarticle/978732

Aug 5th, 2022 - The US Food and Drug Administration has approved AstraZeneca's new tablet formulation of acalabrutinib (Calquence) for all current indications of the capsule version. These include adult patients with chronic lymphocytic leukemia (CLL), small lymp...

'Profound' Results With Ibrutinib Add-On in Mantle Cell Lymphoma 
https://www.medscape.com/viewarticle/975055

Jun 4th, 2022 - Dr Michael Wang The largest trial to date in mantle cell lymphoma shows that adding the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) to standard of care treatment improves progression-free survival (PFS) by 50%. The phase 3 SHINE...

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL
https://www.onclive.com/view/second-line-axi-cel-offers-a-practice-changing-indication-for-lbcl

May 3rd, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...

CAR NK Cell Therapies Show Preliminary Safety and Efficacy in AML, Non-Hodgkin Lymphoma
https://www.onclive.com/view/car-nk-cell-therapies-show-preliminary-safety-and-efficacy-in-aml-non-hodgkin-lymphoma

Apr 25th, 2022 - The novel allogeneic CAR-engineered natural killer (NK) cell therapies, NKX101 and NKX01, showcased early signs of safety and efficacy when utilized in the treatment of heavily pretreated patients with acute myeloid leukemia (AML) and non-Hodgkin ...

Dr. Dietrich on Optimizing Treatment Options for Patients in MCL
https://www.onclive.com/view/dr-dietrich-on-optimizing-treatment-options-for-patients-in-mcl

Apr 12th, 2022 - Martin Dietrich, MD, PhD, physician, Florida Cancer Specialists and Research Institute, assistant professor of internal medicine, University of Central Florida, discusses optimizing treatment options for patients with mantle cell lymphoma (MCL). ...

see more →